BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits pre-clinical activity in Philadelphia chromosome-positive leukemia

BCR-ABL1 tyrosine kinase inhibitors (TKIs) are the cornerstone of treatment in chronic myeloid leukemia. Although there are now four TKIs approved for use in the front-line setting, acquired TKI resistance via secondary kinase domain mutations remains a problem for patients. K706 is a novel BCR-ABL1...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Exp Hematol
Hlavní autoři: Antelope, Orlando, Vellore, Nadeem, Pomicter, Anthony D., Patel, Ami B., van Scoyk, Alexandria, Clair, Phillip M., Deininger, Michael, O’Hare, Thomas
Médium: Artigo
Jazyk:Inglês
Vydáno: 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6803074/
https://ncbi.nlm.nih.gov/pubmed/31493432
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.exphem.2019.08.007
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky